Show simple item record

Files in this item

Item metadata

dc.contributor.authorAndersen, C Yding
dc.contributor.authorFischer, R
dc.contributor.authorGiorgione, V
dc.contributor.authorKelsey, Thomas W
dc.identifier.citationAndersen , C Y , Fischer , R , Giorgione , V & Kelsey , T W 2016 , ' Micro-dose hCG as luteal phase support without exogenous progesterone administration : mathematical modelling of the hCG concentration in circulation and initial clinical experience ' Journal of Assisted Reproduction and Genetics , vol. 33 , no. 10 , pp. 1311-1318 . DOI: 10.1007/s10815-016-0764-7en
dc.identifier.otherPURE: 243605680
dc.identifier.otherPURE UUID: 36daebd2-8660-4de4-8e2c-6d5fd02400a8
dc.identifier.otherPubMed: 27448021
dc.identifier.otherPubMed: 27448021
dc.identifier.otherScopus: 84979587870
dc.descriptionThe University Hospital of Copenhagen and the EU interregional project ReproHigh/ReproUnion are gratefully acknowledged for financial support.en
dc.description.abstractFor the last two decades, exogenous progesterone administration has been used as luteal phase support (LPS) in connection with controlled ovarian stimulation combined with use of the human chorionic gonadotropin (hCG) trigger for the final maturation of follicles. The introduction of the GnRHa trigger to induce ovulation showed that exogenous progesterone administration without hCG supplementation was insufficient to obtain satisfactory pregnancy rates. This has prompted development of alternative strategies for LPS. Augmenting the local endogenous production of progesterone by the multiple corpora lutea has been one focus with emphasis on one hand to avoid development of ovarian hyper-stimulation syndrome and, on the other hand, to provide adequate levels of progesterone to sustain implantation. The present study evaluates the use of micro-dose hCG for LPS support and examines the potential advances and disadvantages. Based on the pharmacokinetic characteristics of hCG, the mathematical modelling of the concentration profiles of hCG during the luteal phase has been evaluated in connection with several different approaches for hCG administration as LPS. It is suggested that the currently employed LPS provided in connection with the GnRHa trigger (i.e. 1.500 IU) is too strong, and that daily micro-dose hCG administration is likely to provide an optimised LPS with the current available drugs. Initial clinical results with the micro-dose hCG approach are presented.en
dc.relation.ispartofJournal of Assisted Reproduction and Geneticsen
dc.rights© 2016, Springer. This work is made available online in accordance with the publisher’s policies. This is the author created, accepted version manuscript following peer review and may differ slightly from the final published version. The final published version of this work is available at /
dc.subjectLuteal phase supporten
dc.subjectCorpus luteum functionen
dc.subjectGnRH agonist triggeren
dc.subjectQA75 Electronic computers. Computer scienceen
dc.subjectQH426 Geneticsen
dc.subjectRG Gynecology and obstetricsen
dc.subjectObstetrics and Gynaecologyen
dc.subjectReproductive Medicineen
dc.subjectDevelopmental Biologyen
dc.titleMicro-dose hCG as luteal phase support without exogenous progesterone administration : mathematical modelling of the hCG concentration in circulation and initial clinical experienceen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Computer Scienceen
dc.contributor.institutionUniversity of St Andrews. Centre for Interdisciplinary Research in Computational Algebraen
dc.description.statusPeer revieweden

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record